Maxiflo Forte Rotacaps are inhalable dry-powder capsules combining a higher dose of fluticasone propionate, a strong inhaled corticosteroid, with formoterol fumarate, a long-acting β₂-agonist. Designed for individuals requiring stepped-up treatment, these capsules help optimize inflammation control and airway relaxation when used with a compatible DPI device.
Select options
This product has multiple variants. The options may be chosen on the product page
Maxiflo Inhaler 125 mcg is a pressurized metered‑dose inhaler that delivers a fixed combination of fluticasone propionate, a potent corticosteroid, and formoterol fumarate, a long-acting β₂‑agonist. This dual-action formulation offers both inflammation control and airway opening in each spray, making it suitable for regular asthma and COPD care.
Select options
This product has multiple variants. The options may be chosen on the product page
Maxiflo Inhaler 250 mcg is a pressurized metered‑dose inhaler (MDI) that combines fluticasone propionate, a potent corticosteroid, with formoterol fumarate, a fast-acting long‑acting β₂-agonist. This dual formulation delivers both inflammation control and airway relaxation in each inhalation, making it ideal for managing asthma and chronic obstructive pulmonary disease (COPD).
Select options
This product has multiple variants. The options may be chosen on the product page
Maxiflo Rotacaps 100 mcg are inhalable dry-powder capsules containing fluticasone propionate, a potent inhaled corticosteroid, and formoterol fumarate, a long-acting β₂-agonist. These capsules are designed for use with a compatible DPI device to reduce airway inflammation and maintain open airways—supported by a portable, propellant-free format suitable for daily asthma and COPD management.
Select options
This product has multiple variants. The options may be chosen on the product page
Maxiflo Rotacaps 250 mcg are inhalable dry‑powder capsules containing a fixed dose of fluticasone propionate, a potent inhaled corticosteroid, and formoterol fumarate, a long-acting β₂‑agonist. These capsules work together to reduce airway inflammation and maintain open airways—ideal for daily management of asthma and COPD when used with a compatible DPI device.
Select options
This product has multiple variants. The options may be chosen on the product page
Medrol 16 mg contains methylprednisolone, a corticosteroid known for its potent anti-inflammatory and immunosuppressive effects. It is used in conditions such as moderate inflammation, autoimmune flare-ups, severe allergies, and respiratory disorders, providing significant relief when used as prescribed.
Medrol 4 mg contains methylprednisolone, a corticosteroid with effective anti-inflammatory and immunosuppressive properties. It is suitable for managing mild to moderate inflammation, allergic reactions, respiratory conditions, and immune-related disorders. The tablet form enables precise dosing, making it ideal for tailoring treatment duration as needed.
Medrol 8 mg contains methylprednisolone, a corticosteroid with significant anti-inflammatory and immunosuppressive properties. It’s appropriate for managing moderate inflammatory diseases, autoimmune flares, acute allergy symptoms, and certain respiratory conditions. The tablet form allows accurate dosing and flexible treatment duration under medical supervision.
Select options
This product has multiple variants. The options may be chosen on the product page
Methylprednisolone LP 4 mg is a controlled-release (LP) oral corticosteroid tablet formulated for sustained anti-inflammatory effect throughout the day. It is intended for conditions requiring consistent steroid delivery such as autoimmune diseases, severe allergic reactions, and chronic inflammatory disorders. The LP (long-acting) design helps maintain stable therapy levels.
Select options
This product has multiple variants. The options may be chosen on the product page
Montair 10 mg is a once-daily oral tablet containing montelukast, a leukotriene receptor antagonist that helps reduce airway inflammation and prevent bronchoconstriction. It’s indicated for adults and adolescents (15 years+) to manage chronic asthma, prevent exercise-induced bronchospasm, and alleviate seasonal or perennial allergic rhinitis.
Select options
This product has multiple variants. The options may be chosen on the product page
Montair Chewable 4 mg is a chewable tablet formulation of montelukast, a leukotriene receptor antagonist that helps reduce airway inflammation and allergic reactions. Designed for children aged 2–5, it assists in preventing airway constriction, exercise-induced asthma, and symptoms of seasonal allergic rhinitis with a dose that’s easy for little ones to take.
Select options
This product has multiple variants. The options may be chosen on the product page
Montair Chewable 5 mg is a chewable tablet containing montelukast, a leukotriene receptor antagonist that helps block inflammation and airway constriction. Indicated for children aged 6–14, it helps prevent asthma exacerbations, manage exercise-induced asthma, and alleviate seasonal or perennial allergy symptoms.
Select options
This product has multiple variants. The options may be chosen on the product page
End of content
End of content
Join our newsletter and get 50% off your first order
Subscribe to our newsletter and get the latest trending products and offers updates.
Wait! before you leave…
We have something special for you
Use above code to get 20% off for your first order when checkout. Don't miss it.